Interdisciplinar teragnosis and radiosomics
INTRA
Institute Catalá Oncología
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Institute Catalá Oncología (7)
2022
-
High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01/05): 10-year results of a phase 3 randomised, controlled trial
The Lancet Oncology, Vol. 23, Núm. 5, pp. 671-681
2021
-
10-Year Results of a Phase III Randomized Trial of High-Dose Radiotherapy and Risk-Adapted Androgen Deprivation in Localized Prostate Cancer
International journal of radiation oncology, biology, physics, Vol. 111, Núm. 3, pp. S77
-
Prognostic value of testosterone castration levels following androgen deprivation and high-dose radiotherapy in localized prostate cancer: Results from a phase III trial
Radiotherapy and Oncology, Vol. 160, pp. 115-119
2020
-
Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors
Science Translational Medicine, Vol. 12, Núm. 565
2016
-
Late Radiation and Cardiovascular Adverse Effects After Androgen Deprivation and High-Dose Radiation Therapy in Prostate Cancer: Results From the DART 01/05 Randomized Phase 3 Trial
International Journal of Radiation Oncology Biology Physics, Vol. 96, Núm. 2, pp. 341-348
2015
-
High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): A randomised, controlled, phase 3 trial
The Lancet Oncology, Vol. 16, Núm. 3, pp. 320-327